6118 (6118) Fair Value & Analysis
Healthcare · Market cap HK$354M
Fair value as of: Jul 2, 2026
From 24 valuation models · updated today
Share price −13.8% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$0.6700 – HK$1.80 · fair‑value band HK$1.26 – HK$2.09 · the HK$0.6900 price screens below the HK$1.68 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
6118 (6118) currently trades at HK$0.6900, while our model-based Fair Value estimate is HK$1.68 — implying the stock looks roughly 143.5% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, 6118 generated revenue of HK$1.5B at a net margin of 2.2%. Revenue grew 8.7% year over year. It earns a return on equity of 4.1%. Net debt stands at HK$67.2M. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
6118 reported revenue of HK$1.5B in FY2025 versus HK$2.0B in FY2021, a compound −6.6%/yr. Reported net income was HK$33.8M in FY2025, compounding −40.9%/yr from FY2021.
Is 6118 fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 1,231 MXN | -23% |
| Abbott Laboratories, ABTT34 | R$39.41 | R$30.42 | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 6118 (6118) undervalued?
What is the fair value of 6118?
What is the quality score of 6118?
What is the revenue of 6118 (6118)?
What is the net profit margin of 6118?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.